ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP83-24 MHCP Pharmacy Benefit Exclusion for Tremfya®, Tecentriq Hybreza™ and Ocrevus Zunovo™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2024
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 841 - 850 လၢ 3159 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP82-24 Enhanced Authorization Submissions through Availity Essentials
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP80-24 Commercial Pharmacy Benefit Exclusion for Select Medications
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
bc-mhcp-pharmprogpolicynotifctn-effective-12-1-24.pdf
ကျိၣ်စ့တၢ်ဂ့ၢ်တၢ်ကျိၤ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
medicaid-dme-008-durable-medical-equipment-rent-to-purchase.pdf
ကျိၣ်စ့တၢ်ဂ့ၢ်တၢ်ကျိၤ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
medicaid-em-013-new-patient.pdf
ကျိၣ်စ့တၢ်ဂ့ၢ်တၢ်ကျိၤ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
commercial-evaluation-management-013-new-patient.pdf
ကျိၣ်စ့တၢ်ဂ့ၢ်တၢ်ကျိၤ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
commercial-lab-path-services-002-professional-component-for-pathology-tests-10.24.23.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
TPO Consent for Disclosure of Part 2 Records
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 01, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P69-24 New Medical and Behavioral Health Policy Management Updates Effective January 6, 2025
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 01, 2024